{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:13Z","timestamp":1793817553769,"version":"4.6.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1,5]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>A novel PI3K\u03b4 inhibitor TGR-1202 synergizes with proteasome inhibitor carfilzomib by silencing c-Myc in preclinical models of lymphoma. The unique activity of TGR-1202 as a single agent and in combination with carfilzomib is driven by an unexpected activity targeting CK1\u03b5.<\/jats:p>","DOI":"10.1182\/blood-2016-08-731240","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T23:28:31Z","timestamp":1477524511000},"page":"88-99","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":101,"title":["Silencing c-Myc translation as a therapeutic strategy through targeting PI3K\u03b4 and CK1\u03b5 in hematological malignancies"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-6086","authenticated-orcid":false,"given":"Changchun","family":"Deng","sequence":"first","affiliation":[{"name":"Center for Lymphoid Malignancies,"},{"name":"Division of Experimental Therapeutics,"},{"name":"Division of Hematology and Oncology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Lipstein","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Scotto","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier O.","family":"Jirau Serrano","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Mangone","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Vendome","sequence":"additional","affiliation":[{"name":"Department of Systems Biology, Howard Hughes Medical Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Xian","family":"Deng","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Realubit","sequence":"additional","affiliation":[{"name":"Joint Centers for Systems Biology-Columbia Genome Center, Columbia University Medical Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Tatonetti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Karan","sequence":"additional","affiliation":[{"name":"Joint Centers for Systems Biology-Columbia Genome Center, Columbia University Medical Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fruman","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Honig","sequence":"additional","affiliation":[{"name":"Department of Systems Biology, Howard Hughes Medical Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald W.","family":"Landry","sequence":"additional","affiliation":[{"name":"Division of Experimental Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies,"},{"name":"Division of Experimental Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019111903485362900_B1","doi-asserted-by":"crossref","first-page":"a014217","DOI":"10.1101\/cshperspect.a014217","article-title":"MYC, metabolism, cell growth, and tumorigenesis","volume":"3","author":"Dang","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"24","key":"2019111903485362900_B2","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1002\/cncr.28899","article-title":"MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches","volume":"120","author":"Petrich","year":"2014","journal-title":"Cancer"},{"issue":"7213","key":"2019111903485362900_B3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nature07260","article-title":"Modelling Myc inhibition as a cancer therapy","volume":"455","author":"Soucek","year":"2008","journal-title":"Nature"},{"issue":"13","key":"2019111903485362900_B4","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1093\/nar\/gks263","article-title":"Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding","volume":"40","author":"Andresen","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"7516","key":"2019111903485362900_B5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature13485","article-title":"RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer","volume":"513","author":"Wolfe","year":"2014","journal-title":"Nature"},{"issue":"8","key":"2019111903485362900_B6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/cgt.2015.34","article-title":"Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells","volume":"22","author":"Thumma","year":"2015","journal-title":"Cancer Gene Ther"},{"issue":"22","key":"2019111903485362900_B7","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1002\/j.1460-2075.1995.tb00257.x","article-title":"Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E","volume":"14","author":"Haghighat","year":"1995","journal-title":"EMBO J"},{"issue":"11","key":"2019111903485362900_B8","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","article-title":"Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism","volume":"13","author":"Gingras","year":"1999","journal-title":"Genes Dev"},{"issue":"42","key":"2019111903485362900_B9","doi-asserted-by":"crossref","first-page":"26457","DOI":"10.1074\/jbc.272.42.26457","article-title":"Regulation of eIF-4E BP1 phosphorylation by mTOR","volume":"272","author":"Hara","year":"1997","journal-title":"J Biol Chem"},{"issue":"12","key":"2019111903485362900_B10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.995802","article-title":"Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1\/eIF4E","volume":"16","author":"Fingar","year":"2002","journal-title":"Genes Dev"},{"issue":"22","key":"2019111903485362900_B11","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2015-02-629485","article-title":"4EBP1\/c-MYC\/PUMA and NF-\u03baB\/EGR1\/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells","volume":"127","author":"Yun","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2019111903485362900_B12","doi-asserted-by":"crossref","first-page":"27819","DOI":"10.18632\/oncotarget.8538","article-title":"Icariside II, a natural mTOR inhibitor, disrupts aberrant energy homeostasis via suppressing mTORC1-4E-BP1 axis in sarcoma cells","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"2019111903485362900_B13","doi-asserted-by":"crossref","first-page":"9488","DOI":"10.18632\/oncotarget.3378","article-title":"Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma","volume":"6","author":"Demosthenous","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"2019111903485362900_B14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.24300","article-title":"TAK-228 (formerly MLN0128), an investigational oral dual TORC1\/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"91","author":"Ghobrial","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111903485362900_B15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.ejca.2011.01.003","article-title":"Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001","volume":"47","author":"Kuo","year":"2011","journal-title":"Eur J Cancer"},{"issue":"3","key":"2019111903485362900_B16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"issue":"7396","key":"2019111903485362900_B17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature"},{"issue":"1","key":"2019111903485362900_B18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1158\/0008-5472.CAN-13-1175","article-title":"Casein kinase 1\u03b5 promotes cell proliferation by regulating mRNA translation","volume":"74","author":"Shin","year":"2014","journal-title":"Cancer Res"},{"issue":"11","key":"2019111903485362900_B19","doi-asserted-by":"crossref","first-page":"e27509","DOI":"10.1371\/journal.pone.0027509","article-title":"S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer","volume":"6","author":"Nawroth","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"2019111903485362900_B20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.molcel.2012.08.003","article-title":"Failure of amino acid homeostasis causes cell death following proteasome inhibition","volume":"48","author":"Suraweera","year":"2012","journal-title":"Mol Cell"},{"issue":"7518","key":"2019111903485362900_B21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nature13492","article-title":"Coordinated regulation of protein synthesis and degradation by mTORC1","volume":"513","author":"Zhang","year":"2014","journal-title":"Nature"},{"issue":"5882","key":"2019111903485362900_B22","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1157535","article-title":"The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1","volume":"320","author":"Sancak","year":"2008","journal-title":"Science"},{"issue":"8","key":"2019111903485362900_B23","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/ncb1753","article-title":"Regulation of TORC1 by Rag GTPases in nutrient response","volume":"10","author":"Kim","year":"2008","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2019111903485362900_B24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1078-0432.CCR-14-0384","article-title":"The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-\u03baB","volume":"21","author":"Deng","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2019111903485362900_B25","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1073\/pnas.1337088100","article-title":"Systematic discovery of multicomponent therapeutics","volume":"100","author":"Borisy","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2019111903485362900_B26","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111903485362900_B27","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1365-2141.2005.05679.x","article-title":"Phosphoinositide 3-kinase\/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias","volume":"130","author":"Tabellini","year":"2005","journal-title":"Br J Haematol"},{"issue":"39","key":"2019111903485362900_B28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jncimonographs\/lgn011","article-title":"Characterization of MYC translocations in multiple myeloma cell lines","author":"Dib","year":"2008","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"2","key":"2019111903485362900_B29","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/jpet.109.151415","article-title":"Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period","volume":"330","author":"Walton","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"22","key":"2019111903485362900_B30","doi-asserted-by":"crossref","first-page":"10307","DOI":"10.1021\/jm301336n","article-title":"Structural basis for the potent and selective inhibition of casein kinase 1 epsilon","volume":"55","author":"Long","year":"2012","journal-title":"J Med Chem"},{"issue":"26","key":"2019111903485362900_B31","doi-asserted-by":"crossref","first-page":"15980","DOI":"10.1074\/jbc.273.26.15980","article-title":"Regulation of casein kinase I epsilon and casein kinase I delta by an in vivo futile phosphorylation cycle","volume":"273","author":"Rivers","year":"1998","journal-title":"J Biol Chem"},{"issue":"22","key":"2019111903485362900_B32","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/onc.2010.627","article-title":"IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1\u03b4\/\u03b5 and Wnt\/\u03b2-catenin independent inhibition of mitotic spindle formation","volume":"30","author":"Cheong","year":"2011","journal-title":"Oncogene"},{"issue":"3","key":"2019111903485362900_B33","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1074\/jbc.273.3.1357","article-title":"Autoinhibition of casein kinase I epsilon (CKI epsilon) is relieved by protein phosphatases and limited proteolysis","volume":"273","author":"Cegielska","year":"1998","journal-title":"J Biol Chem"},{"issue":"5","key":"2019111903485362900_B34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2014.01.007","article-title":"Status of PI3K\/Akt\/mTOR pathway inhibitors in lymphoma","volume":"14","author":"Westin","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2019111903485362900_B35","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"7327","key":"2019111903485362900_B36","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"2019111903485362900_B37","author":"Burris"},{"key":"2019111903485362900_B38","author":"O\u2019Connor"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/1\/88\/1398677\/blood731240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/1\/88\/1398677\/blood731240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:49:08Z","timestamp":1574135348000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/1\/88\/35825\/Silencing-cMyc-translation-as-a-therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,5]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-08-731240","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,5]]}}}